Jean‐Baptiste Hiriart

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.7K citations

Medicine, Oncology, Pharmacology +13

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Thomas Karlas, David Petroff, M. Sasso et al. · Journal of Hepatology · 2016 · 1.2K citations · Full text

Public Health, Health Informatics, Meta-analysis +7

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations

Medicine, Oncology, Radiation Oncology +16

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy

Christophe Cassinotto, Jérôme Boursier, Victor de Lédinghen et al. · Hepatology · 2015 · 514 citations · Full text

Medicine, Pathology, Radiology +17

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

Jérôme Boursier, Julien Vergniol, A. Guillet et al. · Journal of Hepatology · 2016 · 391 citations

Medicine, Internal Medicine, Pathology +17